Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Chlorothiazide

FDA-approved product (suspension, oral), marketed as Chlorothiazide, Diuril, Chlorothiazide Sodium.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Chlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Chronic kidney disease
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with psycholeptics and/or analgesics
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Chlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Chlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide

    NCT02710071 · start 2015-01

    Registered record
    Registry ID
    NCT02710071
    Conditions
    Hypertension
    Interventions
    Nebivolol; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-04
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionNebivolol; Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure

    NCT01647932 · start 2014-10

    Registered record
    Registry ID
    NCT01647932
    Conditions
    Heart Failure
    Interventions
    hydrochlorothiazide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2019-12-15
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    Interventionhydrochlorothiazide; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323

    NCT02094924 · start 2014-04-17

    Registered record
    Registry ID
    NCT02094924
    Conditions
    Hypertension
    Interventions
    GSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-04-17
    Completion
    2014-05-23
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionGSK587323; FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg
    PhasePhase 1
    Registry statusCompleted

  • ACE Inhibitors Combined With Exercise for Seniors - Pilot Study

    NCT01891513 · start 2014-01

    Registered record
    Registry ID
    NCT01891513
    Conditions
    Hypertension; Aging
    Interventions
    Exercise; ACE inhibitor + exercise; Thiazide diuretic + exercise; Angiotensin receptor blocker + exercise
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01
    Completion
    2017-06
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Aging
    InterventionExercise; ACE inhibitor + exercise; Thiazide diuretic + exercise; Angiotensin receptor blocker + exercise
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function

    NCT01977430 · start 2013-11

    Registered record
    Registry ID
    NCT01977430
    Conditions
    Chronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    Interventions
    Hydrochlorothiazide and furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-11
    Completion
    2015-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    InterventionHydrochlorothiazide and furosemide
    PhasePhase 4
    Registry statusUnknown

  • Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide

    NCT01692717 · start 2013-02-28

    Registered record
    Registry ID
    NCT01692717
    Conditions
    Healthy Subjects
    Interventions
    Atorvastatin; Hydrochlorothiazide + Losartan; Hydrochlorothiazide + Losartan + Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-28
    Completion
    2013-05-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionAtorvastatin; Hydrochlorothiazide + Losartan; Hydrochlorothiazide + Losartan + Atorvastatin
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions

    NCT01713647 · start 2012-10

    Registered record
    Registry ID
    NCT01713647
    Conditions
    Fasting
    Interventions
    Amlodipin, losartan, HCTZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2012-12
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasting
    InterventionAmlodipin, losartan, HCTZ
    PhasePhase 1
    Registry statusCompleted

  • To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy

    NCT01302899 · start 2011-01

    Registered record
    Registry ID
    NCT01302899
    Conditions
    Non-diabetic Nephropathy
    Interventions
    Aliskiren; Placebo to Aliskiren; Hydrochlorothiazide (HCTZ); Placebo to Hydrochlorothiazide (HCTZ); Ramipril
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-01
    Completion
    2011-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-diabetic Nephropathy
    InterventionAliskiren; Placebo to Aliskiren; Hydrochlorothiazide (HCTZ); Placebo to Hydrochlorothiazide (HCTZ) +1 more
    PhasePhase 2
    Registry statusTerminated

  • Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

    NCT01033071 · start 2010-01

    Registered record
    Registry ID
    NCT01033071
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-11
    Enrolment
    1,071

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

    NCT00871871 · start 2009-03

    Registered record
    Registry ID
    NCT00871871
    Conditions
    Hypertension
    Interventions
    Hydrochlorothiazide (HCTZ); Comparator: Placebo to HCTZ; Isosorbide mononitrate (ISMN); Comparator: Placebo to ISMN
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHydrochlorothiazide (HCTZ); Comparator: Placebo to HCTZ; Isosorbide mononitrate (ISMN); Comparator: Placebo to ISMN
    PhasePhase 1
    Registry statusCompleted

  • Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

    NCT00787605 · start 2008-11

    Registered record
    Registry ID
    NCT00787605
    Conditions
    Hypertension; Diabetes Mellitus
    Interventions
    Amlodipine; Hydrochlorothiazide (HCTZ); Aliskiren
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-01
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus
    InterventionAmlodipine; Hydrochlorothiazide (HCTZ); Aliskiren
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

    NCT00765947 · start 2008-09

    Registered record
    Registry ID
    NCT00765947
    Conditions
    Essential Hypertension ( Mild to Moderate)
    Interventions
    Aliskiren; Hydrochlorothiazide; Amlodipine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-09
    Completion
    2009-08
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension ( Mild to Moderate)
    InterventionAliskiren; Hydrochlorothiazide; Amlodipine
    PhasePhase 4
    Registry statusCompleted

  • A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

    NCT00667719 · start 2008-06-05

    Registered record
    Registry ID
    NCT00667719
    Conditions
    Essential Hypertension
    Interventions
    Aliskiren; Amlodipine; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-06-05
    Completion
    2009-10-05
    Enrolment
    564

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAliskiren; Amlodipine; Hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

    NCT01712126 · start 2007-09

    Registered record
    Registry ID
    NCT01712126
    Conditions
    Hypertension
    Interventions
    Irbesartan and Hydrochlorothiazide; Avalide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan and Hydrochlorothiazide; Avalide
    PhaseNot applicable
    Registry statusCompleted

  • Regression of Fatty Heart by Valsartan Therapy

    NCT00745953 · start 2007-08

    Registered record
    Registry ID
    NCT00745953
    Conditions
    Metabolic Syndrome; Lipotoxicity
    Interventions
    Valsartan; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2007-08
    Completion
    2009-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Lipotoxicity
    InterventionValsartan; Hydrochlorothiazide
    PhasePhase 4
    Registry statusWithdrawn